Delang L, Vliegen I, Froeyen M, Neyts J. . Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of. Antimicrob Agents Chemother . 2011. 55(9). 4103-4113. Find at Google Scholar.
Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong A. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely. J Virol. . 2013. 87(3). 1544-1553. Find at Google Scholar.
Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, . The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribav. Hepatology . 2012. 55(3) . 749-758. Find at Google Scholar.
Hebner CW, Martin R, Knox S, Miller MD, Mo H, Svaroskaia ES. . The effects of combining two Gilead direct acting antivirals GS-9256GS-9190, ribavirin, and pegylat. 62nd Annual Meeting of the American Associati. 2011. . . Find at Google Scholar.